Levobupivacaine hydrochloride
Based on 2 publication(s) in Google Scholar
Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer.
For research use only. We do not sell to patients.
- Purity: 99.86%
- CAS No.: 27262-48-2
- Formula: C18H29ClN2O
- Molecular Weight:324.89
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Levobupivacaine hydrochloride
More
Biological Activity
Sodium channels, Ferroptosis[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
13 μM
Compound: Levo-(S)-bupivacaine
|
Inhibition of wild-type human ERG channel expressed in CHO cells by whole-cell patch clamp technique
Inhibition of wild-type human ERG channel expressed in CHO cells by whole-cell patch clamp technique
|
[PMID: 21624711] |
| CHO | IC50 |
83 μM
Compound: Levo-(S)-bupivacaine
|
Inhibition of human ERG Y652A mutant channel expressed in CHO cells by whole-cell patch clamp technique
Inhibition of human ERG Y652A mutant channel expressed in CHO cells by whole-cell patch clamp technique
|
[PMID: 21624711] |
| HEK293 | IC50 |
1013 μM
Compound: Levo-(S)-bupivacaine
|
Inhibition of human ERG F656A mutant channel expressed in HEK293 cells assessed as blockade of potassium tail current by whole-cell patch clamp technique
Inhibition of human ERG F656A mutant channel expressed in HEK293 cells assessed as blockade of potassium tail current by whole-cell patch clamp technique
|
[PMID: 21624711] |
| HEK293 | IC50 |
13 μM
Compound: Levo-(S)-bupivacaine
|
Inhibition of wild-type human ERG channel expressed in HEK293 cells assessed as blockade of potassium tail current by whole-cell patch clamp technique
Inhibition of wild-type human ERG channel expressed in HEK293 cells assessed as blockade of potassium tail current by whole-cell patch clamp technique
|
[PMID: 21624711] |
| HEK293 | IC50 |
278 μM
Compound: Levo-(S)-bupivacaine
|
Inhibition of human ERG Y652A mutant channel expressed in HEK293 cells assessed as blockade of potassium tail current by whole-cell patch clamp technique
Inhibition of human ERG Y652A mutant channel expressed in HEK293 cells assessed as blockade of potassium tail current by whole-cell patch clamp technique
|
[PMID: 21624711] |
Levobupivacaine (0-4 mM; 24 h) does not affect the viability of GES-1 cells but inhibits the viability of HGC27 and SGC7901 cells[2].
Levobupivacaine (2 mM; 24, 48 or 72 h) enhances Erastin-induced inhibitory impact on HGC27 and SGC7901 cell viabilities; induces the levels of Fe2+, iron, and lipid ROS[2].
Levobupivacaine (2 mM; 24 h) enhances the expression of miR-489-3p in HGC27 and SGC7901 cells, increases the levels of Fe2+ and iron[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:GES-1, HGC27 and SGC790
-
Concentration:0, 0.5, 1, 2 and 4 mM
-
Incubation Time:24 h
-
Result:Did not affect the viability of normal gastric epithelial GES-1 cell lines but inhibited the viability of HGC27 and SGC7901 cells in a dose-dependent manner.
-
Cell Line:HGC27 and SGC7901 (incubated with 5 μM erastin)
-
Concentration:2 mM
-
Incubation Time:24, 48 or 72 h
-
Result:Enhanced erastin-induced inhibitory impact on HGC27 and SGC7901 cell viabilities; induced the levels of Fe2+, iron, and lipid ROS.
-
Cell Line:HGC27 and SGC7901 (incubated with 5 μM erastin)
-
Concentration:2 mM
-
Incubation Time:24 h
-
Result:Enhanced the expression of miR-489-3p in HGC27 and SGC7901 cells, increased the levels of Fe2+ and iron.
Levobupivacaine (5 or 36 mg/kg; IP; single dosage) increases the latency to partial seizures and prevents the occurrence of generalized seizures at low dosage; reduces the latency to N-methyl-d-aspartate (NMDA)-induced seizures and increased seizure severity at high dosage[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD1 mice (30-35 g; induced epileptic seizures by injecting with NMDA)[3]
-
Dosage:5 or 36 mg/kg
-
Administration:IP; single dosage
-
Result:Increased the latency to partial seizures and prevented the occurrence of generalized seizures at 5 mg/kg; reduced the latency to NMDA-induced seizures and increased seizure severity at 36 mg/kg.
-
Animal Model:SCID nude mice (6-8 weeks; subcutaneously injected with 5×106 SGC7901 cells)[2]
-
Dosage:40 μmol/kg
-
Administration:IP; once daily for 25 days
-
Result:Significantly inhibited SGC7901 cell growth, and enhanced the lipid ROS accumulation.
Chemical Information
-
CAS No. 27262-48-2
-
Appearance Solid
-
Molecular Weight 324.89
-
Formula C18H29ClN2O
-
Color White to off-white
-
SMILES
O=C([C@H]1N(CCCC)CCCC1)NC2=C(C)C=CC=C2C.[H]Cl
-
Synonyms
(S)-(-)-Bupivacaine monohydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Stem Cell Res Ther
Local anesthetics impair the growth and self-renewal of glioblastoma stem cells by inhibiting ZDHHC15-mediated GP130 palmitoylation. [Abstract]2021 Feb 4;12(1):107. PMID: 33541421 -
Eur Spine J
Effect of species, concentration and volume of local anesthetics on intervertebral disk degeneration in rats with discoblock. [Abstract]2022 Nov;31(11):2960-2971. PMID: 36152221
Solvent & Solubility
DMSO : 100 mg/mL (307.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : ≥ 50 mg/mL (153.90 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3 mg/mL (9.23 mM); Clear solution
This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sanford M, et al. Levobupivacaine: a review of its use in regional anaesthesia and pain management. Drugs. 2010 Apr 16;70(6):761-91. [Content Brief]
[2]. Mao SH, et al. Levobupivacaine Induces Ferroptosis by miR-489-3p/SLC7A11 Signaling in Gastric Cancer. Front Pharmacol. 2021 Jun 9;12:681338. [Content Brief]
[3]. Marganella C, et al. Comparative effects of levobupivacaine and racemic bupivacaine on excitotoxic neuronal death in culture and N-methyl-D-aspartate-induced seizures in mice. Eur J Pharmacol. 2005 Aug 22;518(2-3):111-5. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.0780 mL | 15.3898 mL | 30.7796 mL | 76.9491 mL |
| 5 mM | 0.6156 mL | 3.0780 mL | 6.1559 mL | 15.3898 mL | |
| 10 mM | 0.3078 mL | 1.5390 mL | 3.0780 mL | 7.6949 mL | |
| 15 mM | 0.2052 mL | 1.0260 mL | 2.0520 mL | 5.1299 mL | |
| 20 mM | 0.1539 mL | 0.7695 mL | 1.5390 mL | 3.8475 mL | |
| 25 mM | 0.1231 mL | 0.6156 mL | 1.2312 mL | 3.0780 mL | |
| 30 mM | 0.1026 mL | 0.5130 mL | 1.0260 mL | 2.5650 mL | |
| 40 mM | 0.0769 mL | 0.3847 mL | 0.7695 mL | 1.9237 mL | |
| 50 mM | 0.0616 mL | 0.3078 mL | 0.6156 mL | 1.5390 mL | |
| 60 mM | 0.0513 mL | 0.2565 mL | 0.5130 mL | 1.2825 mL | |
| 80 mM | 0.0385 mL | 0.1924 mL | 0.3847 mL | 0.9619 mL | |
| 100 mM | 0.0308 mL | 0.1539 mL | 0.3078 mL | 0.7695 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Levobupivacaine hydrochloride Related Classifications
HY-B0653A Related Classifications
Powered by Bioz